The vaccine, developed byPfizer Inc.and the German company BioNTech, will begin distribution shortly.
The emergency use authorization (EUA) applies to people age 16 and older.
The panel advises more people of color be added to ongoing clinical trials.
Pool / Pool / Getty Images
Offit recommended that studies also be conducted on the vaccine in people with common allergies.
Distribution could begin very soon after that.
The first doses of the vaccine are expected to be administered to healthcare workers and nursing home residents.
Normally, the review process for vaccines studied in tens of thousands of people takes months.
The FDA says that distribution of vaccines could come within 24 hours of authorization.
For the most recent updates on COVID-19, visit ourcoronavirus news page.
Food and Drug Administration.Vaccines and Related Biological Products Advisory Committee meeting.
FDA briefing document: Pfizer-BioNTech COVID-19 vaccine.
Centers for Disease Control and Prevention.Health equity considerations and racial and ethnic minority groups.
Smout A.UK issues anaphylaxis warning on Pfizer vaccine after adverse reactions.
